{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:06:13Z","timestamp":1787317573996,"version":"build-2736575974"},"reference-count":145,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ijbiomac.2025.144151","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T10:58:13Z","timestamp":1747047493000},"page":"144151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Topical delivery of anti-VEGF macromolecules for retinopathy: A review"],"prefix":"10.1016","volume":"312","author":[{"given":"Varaprasad R.","family":"Regu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit P.","family":"Swain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lolly","family":"Pattnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat B.","family":"Subudhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2025.144151_bb0005","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1001\/jama.298.8.944","article-title":"Retinopathy","volume":"298","author":"Torpy","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0010","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.preteyeres.2013.06.002","article-title":"Arginase in retinopathy","volume":"36","author":"Narayanan","year":"2013","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0015","series-title":"Retinopathy, Transplantation of the Pancreas: Second Edition","first-page":"845","author":"Kim","year":"2023"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0020","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1056\/NEJMra032865","article-title":"Hypertensive retinopathy","volume":"351","author":"Wong","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0025","unstructured":"Retinopathy - Harvard Health, (n.d.). https:\/\/www.health.harvard.edu\/a_to_z\/retinopathy-a-to-z (accessed January 20, 2025)."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0030","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/jamaophthalmol.2018.4290","article-title":"Incidence and early course of retinopathy of prematurity: secondary analysis of the postnatal Growth and Retinopathy of Prematurity (G-ROP) study","volume":"136","author":"Quinn","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0035","first-page":"2475","article-title":"Regression patterns of central serous chorioretinopathy using en face optical coherence tomography","volume":"260","author":"Arora","year":"2022","journal-title":"Graefe\u2019s Archive for Clin. Experiment. Ophthalmol."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0040","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/hr.2015.72","article-title":"Hypertension is an independent risk factor for type 2 diabetes: the Korean genome and epidemiology study","volume":"38","author":"Kim","year":"2015","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.amsu.2022.103758","article-title":"Prevalence of hypertension in Type-2 diabetes mellitus","volume":"78","author":"Naseri","year":"2022","journal-title":"Ann. Med. Surg."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0050","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1186\/s12886-023-03118-6","article-title":"Research progress on the pathogenesis of diabetic retinopathy","volume":"23","author":"Li","year":"2023","journal-title":"BMC Ophthalmol."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0055","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","article-title":"Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis","volume":"128","author":"Teo","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0060","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/dom.13550","article-title":"Association between diabetic eye disease and other complications of diabetes: implications for care. A systematic review","volume":"21","author":"Pearce","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0065","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.drudis.2016.10.015","article-title":"Protein delivery to the back of the eye: barriers, carriers and stability of anti-VEGF proteins","volume":"22","author":"Radhakrishnan","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0070","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.723","article-title":"Biological drug therapy for ocular angiogenesis: anti-VEGF agents and novel strategies based on nanotechnology","volume":"9","author":"Formica","year":"2021","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0075","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.drudis.2016.10.015","article-title":"Protein delivery to the back of the eye: barriers, carriers and stability of anti-VEGF proteins","volume":"22","author":"Radhakrishnan","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0080","unstructured":"Drugs@FDA: FDA-Approved Drugs, (n.d.). https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm (accessed April 12, 2025)."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0085","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/17425247.2022.2017878","article-title":"Topical drug delivery to the retina: obstacles and routes to success","volume":"19","author":"Loftsson","year":"2022","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114342","article-title":"Polymer based sustained drug delivery to the ocular posterior segment: barriers and future opportunities for the treatment of neovascular pathologies","volume":"187","author":"Alshaikh","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2020.108329","article-title":"Role of small interfering RNA (siRNA) in targeting ocular neovascularization: a review","volume":"202","author":"Supe","year":"2021","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0100","doi-asserted-by":"crossref","first-page":"2403399","DOI":"10.1002\/advs.202403399","article-title":"Innovative nanotechnology in drug delivery systems for advanced treatment of posterior segment ocular diseases","volume":"11","author":"Wu","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0105","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.trsl.2020.10.003","article-title":"The antidiabetic drug glibenclamide exerts direct retinal neuroprotection","volume":"229","author":"Berdugo","year":"2021","journal-title":"Transl. Res."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0110","doi-asserted-by":"crossref","first-page":"9161039","DOI":"10.1155\/2020\/9161039","article-title":"Metformin treatment is associated with a decreased risk of nonproliferative diabetic retinopathy in patients with type 2 diabetes mellitus: a population-based cohort study","volume":"2020","author":"Fan","year":"2020","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0115","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3390\/ijms23031362","article-title":"The effect of sodium-dependent glucose cotransporter 2 inhibitor Tofogliflozin on neurovascular coupling in the retina in type 2 diabetic mice","volume":"23","author":"Hanaguri","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0120","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0168-8227(88)80046-9","article-title":"Long-term comparison of oral hypoglycemic agents in diabetic retinopathy Gliclazide vs. other sulfonylureas","volume":"5","author":"Akanuma","year":"1988","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0125","series-title":"Systemic Route for Retinal Drug Delivery: Role of the Blood-Retinal Barrier","first-page":"85","author":"Tachikawa","year":"2011"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0130","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2337\/diacare.29.02.06.dc05-1781","article-title":"Lifestyle intervention is associated with lower prevalence of urinary incontinence: the Diabetes Prevention Program","volume":"29","author":"Brown","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0135","first-page":"CD005656","article-title":"Intravitreal steroids for macular edema in diabetes","author":"Grover","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0140","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011234","article-title":"Laser photocoagulation for proliferative diabetic retinopathy","volume":"2014","author":"Evans","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0145","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.sjopt.2014.09.001","article-title":"Modern retinal laser therapy","volume":"29","author":"Kozak","year":"2015","journal-title":"Saudi Journal of Ophthalmology"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0150","article-title":"Different lasers and techniques for proliferative diabetic retinopathy","volume":"2016","author":"Moutray","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0155","first-page":"339","article-title":"Effective mechanisms of laser photocoagulation for neovascularization in diabetic retinopathy","volume":"100","author":"Funatsu","year":"1996","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11892-021-01403-6","article-title":"Laser therapy in the treatment of diabetic retinopathy and diabetic macular edema","volume":"21","author":"Everett","year":"2021","journal-title":"Curr. Diab. Rep."},{"issue":"2007","key":"10.1016\/j.ijbiomac.2025.144151_bb0165","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/sj.eye.6703026","article-title":"Pain response and follow-up of patients undergoing panretinal laser photocoagulation with reduced exposure times","volume":"22:1 22","author":"Al-Hussainy","year":"2008","journal-title":"Eye"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0170","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0161-6420(81)34978-1","article-title":"Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8","volume":"88","author":"Riaskoff","year":"1981","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0175","doi-asserted-by":"crossref","first-page":"e530","DOI":"10.1111\/aos.14312","article-title":"Efficacy and safety of ranibizumab with or without panretinal laser photocoagulation versus laser photocoagulation alone in proliferative diabetic retinopathy \u2013 the PRIDE study","volume":"98","author":"Lang","year":"2020","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0180","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ajo.2019.03.005","article-title":"Anti\u2013vascular endothelial growth factor therapy for diabetic retinopathy: consequences of inadvertent treatment interruptions","volume":"204","author":"Wubben","year":"2019","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0185","doi-asserted-by":"crossref","first-page":"1307860","DOI":"10.3389\/fphar.2023.1307860","article-title":"Recent advances of anti-angiogenic inhibitors targeting VEGF\/VEGFR axis","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2024.101271","article-title":"Resilience to diabetic retinopathy","volume":"101","author":"Serikbaeva","year":"2024","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0195","first-page":"117","article-title":"Intravitreal bevacizumab (avastin) for proliferative diabetic retinopathy: 6-months follow-up","volume":"2009 23:1 23","author":"Arevalo","year":"2007","journal-title":"Eye"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0200","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1136\/bmj.c5400","article-title":"Managing diabetic retinopathy","volume":"341","author":"Ockrim","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0205","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0210","unstructured":"Bevacizumab - EyeWiki, (n.d.). https:\/\/eyewiki.org\/Bevacizumab (accessed April 12, 2025)."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0215","unstructured":"Drugs@FDA: FDA-Approved Drugs, (n.d.). https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm (accessed January 8, 2025)."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0220","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jamaophthalmol.2017.0821","article-title":"Change in diabetic retinopathy through 2 years: secondary analysis of a randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab","volume":"135","author":"Bressler","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0225","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0230","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1167\/iovs.13-13054","article-title":"Intraocular pharmacokinetics of ranibizumab in vitrectomized versus nonvitrectomized eyes","volume":"55","author":"Ahn","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0235","series-title":"Pharmacokinetics of Intravitreally Injected Bevacizumab in Vitrectomized Eyes, Https:\/\/Home.Liebertpub.Com\/Jop","first-page":"612","volume":"29","author":"Ahn","year":"2013"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0240","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/eye.2014.329","article-title":"Intraocular pharmacokinetics of intravitreal vascular endothelial growth factor-Trap in a rabbit model","volume":"2015 29:4 29","author":"Park","year":"2015","journal-title":"Eye"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0245","first-page":"695","article-title":"Ocular half-life of intravitreal biologics in humans and other species: meta-analysis and model-based prediction","volume":"17","author":"Caruso","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0250","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1167\/iovs.13-13054","article-title":"Intraocular pharmacokinetics of ranibizumab in vitrectomized versus nonvitrectomized eyes","volume":"55","author":"Ahn","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0255","series-title":"Pharmacokinetics of Intravitreally Injected Bevacizumab in Vitrectomized Eyes, Https:\/\/Home.Liebertpub.Com\/Jop","first-page":"612","volume":"29","author":"Ahn","year":"2013"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2019.107823","article-title":"In vivo characterization of RC28-E, a fusion protein targeting VEGF and bFGF: pharmacokinetics and ocular distribution in primates","volume":"190","author":"Jiang","year":"2020","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0265","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.addr.2018.01.008","article-title":"Ocular delivery of proteins and peptides: challenges and novel formulation approaches","volume":"126","author":"Mandal","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0270","first-page":"4996","article-title":"Intraocular and systemic pharmacokinetics of brolucizumab (RTH258) in nonhuman primates","volume":"57","author":"Nimz","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0275","first-page":"4926","article-title":"Intravitreal half-lives of aflibercept and brolucizumab in rabbit measured using in vivo fluorophotometry","volume":"61","author":"Romano","year":"2020","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0280","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.addr.2021.04.007","article-title":"Recent trends in drug-delivery systems for the treatment of diabetic retinopathy and associated fibrosis","volume":"173","author":"Silva","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0285","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00417-013-2495-0","article-title":"Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes","volume":"252","author":"Moisseiev","year":"2014","journal-title":"Graefe\u2019s Archive for Clin. Experiment. Ophthalmol."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2022.109162","article-title":"Quantitative pharmacokinetic analyses of anterior and posterior elimination routes of intravitreal anti-VEGF macromolecules using published human and rabbit data","volume":"222","author":"Lamminsalo","year":"2022","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0295","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1167\/iovs.12-10260","article-title":"Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach","volume":"54","author":"Xu","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0300","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.1167\/iovs.17-22431","article-title":"Systemic biodistribution and intravitreal pharmacokinetic properties of bevacizumab, ranibizumab, and aflibercept in a nonhuman primate model","volume":"58","author":"Christoforidis","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0305","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","article-title":"Pharmacokinetics of intravitreal bevacizumab (Avastin)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0310","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/jphp.13273","article-title":"Drug repositioning: a brief overview","volume":"72","author":"Jourdan","year":"2020","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0315","unstructured":"Home | ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ (accessed January 7, 2025)."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0320","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000513048","article-title":"Brolucizumab: a newly developed anti-VEGF molecule for the treatment of neovascular age-related macular degeneration","volume":"244","author":"Tadayoni","year":"2021","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0325","first-page":"3206","article-title":"Brolucizumab for the treatment of proliferative diabetic retinopathy (PDR): 54-week results from the CONDOR study","volume":"65","author":"Kim","year":"2024","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0330","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.2337\/diacare.26.9.2653","article-title":"Diabetic retinopathy and diabetic macular EdemaPathophysiology, screening, and novel therapies","volume":"26","author":"Ciulla","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0335","first-page":"1","article-title":"Evaluating initial responses to brolucizumab in patients undergoing conventional anti-VEGF therapy for diabetic macular edema: a retrospective, single-center, observational study","volume":"2023 13:1 13","author":"Hirano","year":"2023","journal-title":"Scientific Reports"},{"issue":"2022","key":"10.1016\/j.ijbiomac.2025.144151_bb0340","first-page":"9424","article-title":"Aflibercept versus faricimab in the treatment of neovascular age-related macular degeneration and diabetic macular edema: a review","volume":"23","author":"Sebasti\u00e1n","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0345","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"J.S. Heier","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0350","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1167\/iovs.64.13.31","article-title":"Turnover of microaneurysms after intravitreal injections of faricimab for diabetic macular edema","volume":"64","author":"Takamura","year":"2023","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0355","unstructured":"Faricimab - EyeWiki, (n.d.). https:\/\/eyewiki.org\/Faricimab (accessed January 8, 2025)."},{"issue":"2019","key":"10.1016\/j.ijbiomac.2025.144151_bb0360","doi-asserted-by":"crossref","first-page":"644","DOI":"10.3390\/biom9110644","article-title":"Pharmacology study of the multiple angiogenesis inhibitor RC28-E on anti-fibrosis in a chemically induced lung injury model","volume":"9","author":"Kou","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0365","first-page":"935","article-title":"Protective effects of a novel drug RC28-E blocking both VEGF and FGF2 on early diabetic rat retina","volume":"11","author":"Yang","year":"2018","journal-title":"Int. J. Ophthalmol."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0370","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00417-014-2746-8","article-title":"Effect of sulodexide in patients with non-proliferative diabetic retinopathy: diabetic retinopathy sulodexide study (DRESS)","volume":"253","author":"Song","year":"2015","journal-title":"Graefe\u2019s Archive for Clin. Experiment. Ophthalmol."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0375","article-title":"Changes of the serum properties and its effect on the endothelial cells restoration in patients with chronic venous disease treated with sulodexide","volume":"12","author":"Zieli\u0144ski","year":"2024","journal-title":"J. Vasc. Surg. Venous Lymphat. Disord."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0380","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF02591420","article-title":"Antithrombotic and thrombolytic activity of sulodexide in rats","volume":"22","author":"Barbanti","year":"1992","journal-title":"Int. J. Clin. Lab. Res."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0385","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2174\/1570161111666131126144025","article-title":"Sulodexide down-regulates the release of cytokines, chemokines, and leukocyte colony stimulating factors from human macrophages: role of glycosaminoglycans in inflammatory pathways of chronic venous disease","volume":"12","author":"Mannello","year":"2014","journal-title":"Curr. Vasc. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0390","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.2174\/1389450121666200428101738","article-title":"New anti-VEGF drugs in ophthalmology","volume":"21","author":"Campa","year":"2020","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114864","article-title":"Ocular therapies with biomacromolecules: from local injection to eyedrop and emerging noninvasive delivery strategies","volume":"197","author":"Fan","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0400","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1167\/iovs.04-1051","article-title":"Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity","volume":"46","author":"Pitk\u00e4nen","year":"2005","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0405","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.biopha.2018.08.138","article-title":"A review on recent drug delivery systems for posterior segment of eye","volume":"107","author":"Nayak","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0410","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.addr.2018.01.008","article-title":"Ocular delivery of proteins and peptides: challenges and novel formulation approaches","volume":"126","author":"Mandal","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0415","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jconrel.2021.04.008","article-title":"Challenges and strategies for the delivery of biologics to the cornea","volume":"333","author":"Wels","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0420","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.drudis.2019.05.037","article-title":"Hydrogels for sustained delivery of biologics to the back of the eye","volume":"24","author":"Chang","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0425","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1097\/IAE.0000000000002212","article-title":"Long-term physical stability, sterility, and anti-vegf bioactivity of repackaged bevacizumab in 2-ml glass vials","volume":"39","author":"Peterson","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0430","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.xphs.2020.09.043","article-title":"Long-term stability of Anti-Vascular Endothelial Growth Factor (a-VEGF) biologics under physiologically relevant conditions and its impact on the development of long-acting delivery systems","volume":"110","author":"Chang","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0435","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/02713683.2020.1830117","article-title":"Stability of cell-penetrating peptide anti-VEGF formulations for the treatment of age-related macular degeneration","volume":"46","author":"Nikoi","year":"2021","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0440","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.addr.2021.03.014","article-title":"Biologics and their delivery systems: trends in myocardial infarction","volume":"173","author":"Borrelli","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0445","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.addr.2021.04.006","article-title":"Particle engineering principles and technologies for pharmaceutical biologics","volume":"174","author":"Cun","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0450","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.tips.2021.08.005","article-title":"Nanocarriers for oral delivery of biologics: small carriers for big payloads","volume":"42","author":"Cao","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114342","article-title":"Polymer based sustained drug delivery to the ocular posterior segment: barriers and future opportunities for the treatment of neovascular pathologies","volume":"187","author":"Alshaikh","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0460","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.drudis.2016.10.015","article-title":"Protein delivery to the back of the eye: barriers, carriers and stability of anti-VEGF proteins","volume":"22","author":"Radhakrishnan","year":"2017","journal-title":"Drug Discov. Today"},{"issue":"2021","key":"10.1016\/j.ijbiomac.2025.144151_bb0465","first-page":"1","article-title":"Predicting cell-penetrating peptides using machine learning algorithms and navigating in their chemical space","volume":"11:1 11","author":"de Oliveira","year":"2021","journal-title":"Scientific Reports"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0470","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jconrel.2018.06.023","article-title":"Cell penetrating peptides in ocular drug delivery: state of the art","volume":"284","author":"Pescina","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0475","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1167\/iovs.16-20072","article-title":"Topical delivery of anti-VEGF drugs to the ocular posterior segment using cell-penetrating peptides","volume":"58","author":"de Cogan","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0480","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/IAE.0000000000000428","article-title":"Penetration of bevacizumab and ranibizumab through retinal pigment epithelial layer in vitro","volume":"35","author":"Terasaki","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0485","doi-asserted-by":"crossref","first-page":"19256","DOI":"10.1021\/acsami.6b04551","article-title":"Facile noninvasive retinal gene delivery enabled by penetratin","volume":"8","author":"Liu","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0490","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.cclet.2021.08.020","article-title":"Liposome-based delivery of biological drugs","volume":"33","author":"Thapa Magar","year":"2022","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0495","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/smll.201303433","article-title":"Topical delivery of Avastin to the posterior segment of the eye in vivo using Annexin A5-associated liposomes","volume":"10","author":"Davis","year":"2014","journal-title":"Small"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0500","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11080365","article-title":"Pharmacokinetics of intravitreal anti-VEGF drugs in age-related macular degeneration","volume":"11","author":"Garc\u00eda-Quintanilla","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0505","doi-asserted-by":"crossref","first-page":"2108360","DOI":"10.1002\/adma.202108360","article-title":"Antiangiogenic nanomicelles for the topical delivery of aflibercept to treat retinal neovascular disease","volume":"34","author":"Zhao","year":"2022","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0510","doi-asserted-by":"crossref","first-page":"2314126","DOI":"10.1002\/adma.202314126","article-title":"Enhanced ocular delivery of Beva via ultra-small polymeric micelles for noninvasive anti-VEGF therapy","volume":"36","author":"Yang","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0515","series-title":"Novel Strategies for Anterior Segment Ocular Drug Delivery, Https:\/\/Home.Liebertpub.Com\/Jop","first-page":"106","volume":"29","author":"Cholkar","year":"2013"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124265","article-title":"Tamarind seed polysaccharide-metformin insert: higher ocular retention, slow-release, and efficacy against corneal burn","volume":"659","author":"Regu","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0525","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11095-018-2368-7","article-title":"Formulation stabilization and disaggregation of bevacizumab, ranibizumab and aflibercept in dilute solutions","volume":"35","author":"Giannos","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0530","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/19420862.2015.1112477","article-title":"Rational design of therapeutic mAbs against aggregation through protein engineering and incorporation of glycosylation motifs applied to bevacizumab","volume":"8","author":"Courtois","year":"2016","journal-title":"MAbs"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0535","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejps.2017.05.019","article-title":"Biophysical study of bevacizumab structure and bioactivity under thermal and pH-stresses","volume":"105","author":"Sousa","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0540","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ejpb.2023.06.014","article-title":"Topical ocular protein delivery based on protein powder suspensions in semifluorinated alkanes","volume":"189","author":"Marschall","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0545","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s11095-024-03721-2","article-title":"Topical solution for retinal delivery: bevacizumab and ranibizumab eye drops in Anti-Aggregation Formula (AAF) in rabbits","volume":"41","author":"Giannos","year":"2024","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0550","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1444-0938.2010.00553.x","article-title":"Drug delivery to the posterior segment of the eye through hydrogel contact lenses","volume":"94","author":"Schultz","year":"2011","journal-title":"Clin. Exp. Optom."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0555","doi-asserted-by":"crossref","first-page":"212","DOI":"10.2174\/1871520615666150611110354","article-title":"Brain delivery of chemotherapeutics in brain Cancer","volume":"16","author":"Subudhi","year":"2015","journal-title":"Anticancer Agents Med Chem."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0560","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1167\/iovs.06-1171","article-title":"Penetration of bevacizumab through the retina after intravitreal injection in the monkey","volume":"48","author":"Heiduschka","year":"2007","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0565","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/bjophthalmol-2013-304019","article-title":"Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes","volume":"98","author":"Julien","year":"2014","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0570","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.1167\/iovs.17-22431","article-title":"Systemic biodistribution and intravitreal pharmacokinetic properties of bevacizumab, ranibizumab, and aflibercept in a nonhuman primate model","volume":"58","author":"Christoforidis","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0575","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.2337\/diacare.25.7.1248","article-title":"Dysfunction of active transport of blood-retinal barrier in patients with clinically significant macular edema in type 2 diabetes","volume":"25","author":"Mori","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0580","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1021\/mp0499499","article-title":"Identification of a Na+-dependent cationic and neutral amino acid transporter, B(0,+), in human and rabbit cornea","volume":"1","author":"Jain-Vakkalagadda","year":"2004","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0585","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1167\/iovs.16-19162","article-title":"Expression profiling of ascorbic acid-related transporters in human and mouse eyes","volume":"57","author":"Ma","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0590","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1152\/physrev.00025.2013","article-title":"The organic anion transporter (OAT) family: a systems biology perspective","volume":"95","author":"Nigam","year":"2015","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0595","doi-asserted-by":"crossref","first-page":"6718566","DOI":"10.1155\/2022\/6718566","article-title":"Monocarboxylate transporters: role and regulation in corneal diabetes","volume":"2022","author":"Shrestha","year":"2022","journal-title":"Anal. Cell. Pathol."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0600","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2017.12.009","article-title":"Expression, activity and pharmacokinetic impact of ocular transporters","volume":"126","author":"Vellonen","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0605","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1146\/annurev-pharmtox-010814-124852","article-title":"Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier","volume":"55","author":"Lajoie","year":"2015","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0610","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2023.07.028","article-title":"Selective drug delivery to the retinal cells: biological barriers and avenues","volume":"361","author":"Ramsay","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0615","doi-asserted-by":"crossref","DOI":"10.1208\/s12248-018-0270-1","article-title":"Conjugation to ascorbic acid enhances brain availability of losartan carboxylic acid and protects against parkinsonism in rats","volume":"20","author":"Subudhi","year":"2018","journal-title":"AAPS J."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0620","first-page":"2492","article-title":"Ocular delivery of metformin for sustained release and in vivo efficacy","volume":"122","author":"Regu","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0625","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1021\/jm015556r","article-title":"Design, synthesis and activity of ascorbic acid prodrugs of nipecotic, kynurenic and diclophenamic acids, liable to increase neurotropic activity","volume":"45","author":"Manfredini","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0630","doi-asserted-by":"crossref","first-page":"5480","DOI":"10.1073\/pnas.1218165110","article-title":"Structure-based ligand discovery for the large-neutral amino acid transporter 1, LAT-1","volume":"110","author":"Geier","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0635","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1002\/cmdc.201402281","article-title":"Quantitative insight into the design of compounds recognized by the L-type amino acid transporter 1 (LAT1)","volume":"9","author":"Ylikangas","year":"2014","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0640","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/s00044-014-1172-0","article-title":"Development of reversible glutamine conjugate of methotrexate for enhanced brain delivery","volume":"24","author":"Singh","year":"2015","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0645","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13568-019-0869-3","article-title":"Recombinant expressing angiopep-2 fused anti-VEGF single chain Fab (scFab) could cross blood\u2013brain barrier and target glioma","volume":"9","author":"Ji","year":"2019","journal-title":"AMB Express"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0650","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1021\/acs.jmedchem.3c01835","article-title":"Peptide\u2212drug conjugates: an emerging direction for the next generation of peptide therapeutics published as part of the Journal of Medicinal Chemistry virtual special issue \u201cCelebrating the 60th Anniversary of the MIKIW Meeting-in-Miniature\u201d","volume":"67","author":"Dean","year":"2024","journal-title":"J Med Chem"},{"issue":"2019","key":"10.1016\/j.ijbiomac.2025.144151_bb0655","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.3390\/molecules24101855","article-title":"Peptide conjugates with small molecules designed to enhance efficacy and safety","volume":"24","author":"He","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0660","first-page":"23","article-title":"Design and evaluation of ocular controlled delivery system for diclofenac sodium","volume":"14","author":"Jafariazar","year":"2015","journal-title":"Iran J Pharm Res"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0665","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2165\/00003088-200241070-00003","article-title":"Clinical pharmacokinetics of depot leuprorelin","volume":"41","author":"Periti","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0670","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114904","article-title":"Strategies for overcoming protein and peptide instability in biodegradable drug delivery systems","volume":"199","author":"Shi","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0675","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1039\/D1CB00067E","article-title":"Aggregation of protein therapeutics enhances their immunogenicity: causes and mitigation strategies","volume":"2","author":"Lundahl","year":"2021","journal-title":"RSC Chem Biol"},{"issue":"2021","key":"10.1016\/j.ijbiomac.2025.144151_bb0680","first-page":"361","article-title":"Ocular benzalkonium chloride exposure: problems and solutions","volume":"36:2 36","author":"Goldstein","year":"2021","journal-title":"Eye"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0685","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1163\/156856200744101","article-title":"Controlled release of vascular endothelial growth factor by use of collagen hydrogels","volume":"11","author":"Tabata","year":"2000","journal-title":"J. Biomater. Sci. Polym. Ed."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0690","article-title":"A scalable platform for fabricating biodegradable microparticles with pulsatile drug release","volume":"35","author":"Graf","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0695","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.xphs.2018.09.029","article-title":"Impact of ethylene oxide sterilization of polymer-based prefilled syringes on chemical degradation of a model therapeutic protein during storage","volume":"108","author":"Funatsu","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0700","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.freeradbiomed.2005.09.012","article-title":"Protein modification caused by a high dose of gamma irradiation in cryo-sterilized plasma: protective effects of ascorbate","volume":"40","author":"Zbikowska","year":"2006","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0705","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jps.20727","article-title":"Antibody structure, instability, and formulation","volume":"96","author":"Wang","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0710","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","article-title":"Pharmacokinetic aspects of retinal drug delivery","volume":"57","author":"del Amo","year":"2017","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0715","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jconrel.2019.07.033","article-title":"Enhanced anti-angiogenic effects of bevacizumab in glioblastoma treatment upon intranasal administration in polymeric nanoparticles","volume":"309","author":"Sousa","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2025.144151_bb0720","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","article-title":"Pharmacokinetic aspects of retinal drug delivery","volume":"57","author":"del Amo","year":"2017","journal-title":"Prog. Retin. Eye Res."},{"issue":"2021","key":"10.1016\/j.ijbiomac.2025.144151_bb0725","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3390\/pharmaceutics13010122","article-title":"Unlocking the power of exosomes for crossing biological barriers in drug delivery","volume":"13","author":"Elliott","year":"2021","journal-title":"Pharmaceutics"}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025047038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025047038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T01:11:59Z","timestamp":1784682719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813025047038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":145,"alternative-id":["S0141813025047038"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.144151","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topical delivery of anti-VEGF macromolecules for retinopathy: A review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.144151","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"144151"}}